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Summary We have recently succeeded in producing transgenic mice carrying a hybrid gene consisting of
mouse metallothionein promoter-enhancer and the ret oncogene (MT/ret). (Iwamoto et al., 1991b). A
retroperitoneal tumour developed in one of 17 MT/ret transgenic founder mice. Histological analysis revealed
that the tumour consisted of undifferentiated neuroblasts and differentiated ganglion cells, the latter of which
were strongly postitive for neuron specific enolase. Expression of the ret transgene was observed at high levels
in RNA from the tumour, but not in those of other normal tissues. In addition, a 1OOkDa ret protein was
detected in the cell lysate of the tumour. Taken together with our previous data, these results suggest a
possible role for the ret oncogene in the proliferation of neural crest cells.
The ret proto-oncogene encodes a receptor type tyroine
kinase (Takahashi et al., 1988a, 1989; Tahira et al., 1990) and
is frequently expressed in human neuroblastoma, pheoch-
romocytoma and thyroid medullary carcinoma that originate
from neural crest cells (Takahashi & Cooper, 1987; Nagao et
al., 1990; Ikeda et al., 1990; Santoro et al., 1990; Takahashi
et al., 1991). Although a ligand for the ret proto-oncogene
product has not been identified, this finding suggests that the
ret proto-oncogene might play a role in the differentiation or
proliferation of neural crest cells.
The ret oncogene is a hybrid gene of the ret proto-
oncogene and a 'zinc finger'-containing gene (rfp) (Takahashi
et al., 1985; Takahashi & Cooper, 1987; Takahashi et al.,
1988b). This hybrid gene was generated by DNA rearrange-
ment which occurred during the transfection assay. We
recently reported the establishment of transgenic mice that
carried the ret oncogene driven by a mouse metallothionein
regulatory element (Iwamoto et al., 1991b). We obtained 17
founder mice, four of which unexpectedly showed severe
pigmentation in their whole skin, resulting from proliferation
of melanin-producing cells. Melanocytic tumours developed
in three of the four mice with the pigmented skin. Northern
blot and in situ hybridisation experiments indicated that the
ret transgene was expressed preferentially in melanin-
producing cells. These results indicated that the MT/ret gene
affected the proliferation or differentiation of part of the
neural crest cells in our transgenic mice. In addition to these
mice, we found the development of a retroperitoneal tumour
in one MT/ret founder mouse (Iwamoto et al., 1991b). In the
present study, we report the characterisation of this tumour
that was histologically diagnosed as a neuroblastoma.
Material and methods
Mice
The methods to produce the MT/ret transgenic mice were
described previously (Iwamoto et al., 1991b).
Antibody
A polyclonal antibody was developed against the tyrosine
kinase domain of the Ret protein (Takahashi et al., 1991).
Briefly, a fragment of the ret cDNA was inserted into the
pET expression vector and the resulting recombinant plasmid
was transformed into E. coli BL(DE3) strain carrying a single
copy of the gene for T7 RNA polymerase under control of
the lacUV5 promoter. The Ret protein was induced with
isopropyl-p-D-thiogalactopyranoside (IPTG). The protein
was then subjected to SDS-polyacrylamide gels and recovered
by electroelution. Rabbits were immunised five times sub-
cutaneously with 500 Ag of the protein in Freund's
adjuvant.
Anti-phosphotyrosine (PTYR) antibody was purified by
affinity chromatography from the sera of the rabbits
immunised with v-abl-encoded bacterial protein (Hamaguchi
et al., 1988).
Immunohistochemistry
Paraffin sections of neuroblastoma were stained with anti-
neuron specific enolase antibody by a peroxidase anti-
peroxidase (PAP) method (Wajjwalku et al., 1991).
Northern hybridisation
Total cellular RNA (15fig) was isolated by a single step
method (Chomczynski & Sacchi, 1987), separated using
agarose formaldehyde gels and transferred to nylon mem-
branes (Amersham, UK). The probe used for this analysis is
a PstI-PstI fragment of the kinase domain of the ret
oncogene (Iwamoto et al., 1990, 1991a). Prehybridisation,
hybridisation and washes were performed as described
previously (Iwamoto et al., 1990).
Western blotting
Total cell lysates were prepared from tissues of MT/ret trans-
genic mice (Iwamoto et al., 1991b) as described previously
(Takahashi et al., 1991). The lysates were subjected to SDS-
polyacrylamide gel electrophoresis and transferred to nit-
rocellulose (Schleicher & Schuell, Germany) or poly-
vinylidene difluoride (PVDF) (Nihon Millipore Kogyo K.K.,
Yonezawa, Japan) membranes. Reaction with anti-Ret
antibody was performed by the avidin-biotin complex
immunoperoxidase method. Colour development was per-
formed using the POD immunostain set (Wako Pure
Chemical Ind., Ltd., Osaka, Japan). In the case where the
anti-PTYR antibody was used as the first antibody, the
membranes were probed with '25I-protein A (ICN, Irvine,
CA, USA).
Results and discussion
One founder male (designated 301) of the MT/ret transgenic
mice developed a tumour on the back at 3 months of age.
Since the tumour grew rapidly, the animal was sacrificed at
3.5 months of age. The tumour occupied the right ret-
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roperitoneum and involved the right kidney and the adrenal
gland (data now shown).
Histologically, the tumour consisted of undifferentiated
neuroblasts (Figure la) and differentiated ganglion cells
(Figure lb). The former were small round cells with round
nuclei and scanty cytoplasm and the latter were large cells
with large nuclei and basophilic cytoplasm. The tumour was
also characterised by an eosinophilic fibrillar matrix that
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Figure 1 Histopathology of a retroperitoneal tumour. The
tumour consisted of undifferentiated neuroblasts a, and
differentiated ganglion cells b, (Hematoxylin and eosin staining).
Asterisks indicate eosinophilic fibrillar matrix. c, Histochemical
analysis of the tumour by anti-neuron specific enolase antibody.
The ganglion cells were strongly stained. Magnification x 270.
corresponded to nerve fibers (Figure la). Histochemical
analysis indicated that the ganglion cells were strongly
positive for neuron specific enolase, while neuroblasts were
weakly stained (Figure lc). On the other hand, neither of
these cells were reactive with anti S-100 antibody (data not
shown). Thus the tumour was diagnosed as a neuroblastoma
or ganglioneuroblastoma.
We analysed the transgene expression in RNAs from
several tissues of the transgenic mouse. As shown in Figure
2, a 4.5kb transcript of the transgene was detected in the
tumour, using a 3' ret cDNA probe corresponding to the
tyrosine kinase domain (Figure 2). A 5' ret cDNA probe
corresponding to the rfp sequence also detected the same
4.5kb transcript (data not shown), indicating that this tran-
script was derived from the transgene. In other tissues, its
expression was weak or undetectable.
Our recent study (Taniguchi et al., 1992) demonstrated
that the Ret proteins were expressed as 100kDa and 96kDa
glycoproteins in melanocytic tumours which developed in
MT/ret transgenic mice (Figure 3). These proteins were not
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Figure 2 Norther blot analysis of the transgene. Total cellular RNAs (15 jig) isolated from various tissues of the transgenic mouse
(301) were applied to each lane. The blot was hybridised with a 0.55kb PstI-PstI ret cDNA probe containing part of the tyrosine
kinase domain (Iwamoto et al., 1990, 1991a). The positions of 28S and 18S ribosomal RNA are indicated.
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Figure 3 Western blot analysis of the Ret proteins. Lysates
containing 20pg of proteins from a melanocytic tumour and
neuroblastoma developed in MTlret transgenic mice and from
normal liver and kidney of an MTlret transgenic mouse were
separated on 8% SDS-polyacrylamide gel and analysed by
Western blotting with normal rabbit IgG (IOpgml-, lanes a), or
anti-Ret polyclonal antibody (10a gml-b, lanes b,) lOOkDa and
96kDa Ret proteins are indicated.
detected in the lysates from normal liver and kidney of a
transgenic mouse with melanocytic tumours. The same
100kDa Ret protein was also observed in the cell lysate of
the neuroblastoma, while the presence of a 96kDa Ret pro-
tein was unclear (Figure 3). Rather, the anti-Ret antibody
recognised a broad band of 93 to I100kDa in the lysate of the
neuroblastoma, suggesting that part of the Ret proteins
might have been degraded.
To examine phosphotyrosine (PTYR)-containing proteins
in the neuroblastoma, the lysate was reacted with an anti-
PTYR antibody. As shown in Figure 4, a tuokDa band was
detected in the neuroblastoma as well as in the melanocytic
tumour. On the other hand, this eeokDa phos horylated
band was absent in the lysates from normal liver and kidney
of an MTlret transgenic mouse. Since the electrophoretic
mobility of this band was consistent with the lyskDa Ret
protein, it is possible that the 100kDa phosphorylated band
represented the Ret protein. In addition, the level of tyrosine
phosphorylation in neuroblastoma cells seemed to be lower
than that in melanocytic tumour cells (Figure 4).
Although several kinds of transgenic mice carrying
oncogenes driven by a metallothionein regulatory unit have
been produced (Messing et al., 1985; Ruther et al., 1987;
Heisterkamp et al., 1990), there have been no reports of
development of neuroblastoma. In addition, there was no
spontaneous development of neuroblastoma in the MTlret
transgenic mice. It is known that the ret proto-oncogene is
expressed at high levels in human neuroblastomas (Takahashi
& Cooper, 1987; Ikeda et al., 1990; Nagao et al., 1990;
Takahashi et al., 1991). Thus, it is interesting that neuroblas-
toma developed in an MTlret transgenic mouse. Since the
Ret proteins are present as membrane-bound glycoproteins
like the proto-Ret proteins (Taniguchi et al., 1992), it is






Figure 4 Detection of phosphotyrosine-containing proteins.
Lysates containing 50plg of proteins from tissues described in
Figure 3 were analysed by Western blotting with anti-
phosphotyrosine antibody. A l00kDa phosphorylated band is
indicated.
tion of neuroblasts. The fact that four of 17 MT/ret trans-
genic founder mice displayed disorders ofmelanoblasts which
also originate from the neural crest cells (Iwamoto et al.,
1991b) suggested that the MTlret transgene is expressed
preferentially in these cell types. The sequence present in the
MTlret fusion gene may be responsible for this unique ex-
pression pattern in our transgenic mice. Analysis by in situ
hybridisation is necessary to elucidate the precise expression
pattern of the ret oncogene during embryogenesis of the
MTlret transgenic mice.
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